Chapter 32 — Hypothalamic Pharmacology — Module 2 — GnRH Analogs in Clinical Practice
1. [CASE 1 — QUESTION 1]
A 72-year-old man presents with severe low back pain and new bilateral leg weakness. MRI shows extensive vertebral metastases with epidural tumor at T10–T11 abutting the spinal cord, and biopsy confirms metastatic prostate adenocarcinoma with a PSA of 310 ng/mL. The inpatient oncology team plans urgent radiotherapy and wants to start androgen deprivation. A trainee suggests beginning leuprolide depot immediately as monotherapy. Which of the following best explains why GnRH agonist monotherapy is unsafe as the sole initiating strategy in this specific patient?
A) GnRH agonist monotherapy is unsafe because the depot formulation releases drug too slowly to achieve any testosterone suppression within the first month, leaving the cancer untreated during a critical window
B) GnRH agonist monotherapy is unsafe because leuprolide directly stimulates osteoblastic metastases to expand, mechanically compressing the cord independent of any hormonal effect
C) GnRH agonist monotherapy is unsafe because initial receptor activation drives an LH and FSH surge that transiently raises testosterone 50 to 80% above baseline for 1 to 2 weeks; in a patient with epidural disease abutting the cord, this testosterone flare can precipitate or worsen spinal cord compression
D) GnRH agonist monotherapy is unsafe because leuprolide lowers testosterone too rapidly, and the abrupt withdrawal of androgen support causes acute vertebral collapse at metastatic sites
E) GnRH agonist monotherapy is unsafe because agonists cause immediate complement-mediated anaphylaxis in patients with high tumor burden, a risk that is dose-dependent on PSA level
ANSWER: C
Rationale:
GnRH agonists initially activate the GnRH receptor before downregulation occurs. This initial activation couples to Gq/11, drives an LH and FSH surge, and transiently raises serum testosterone 50 to 80% above baseline for the first 1 to 2 weeks — the testosterone flare. In a patient with epidural metastatic disease abutting the spinal cord and early neurologic deficit, this surge in testosterone can stimulate tumor activity and precipitate or worsen spinal cord compression, a neurologic emergency. For this reason, agonist monotherapy is unsafe here; the patient should receive a GnRH antagonist (no flare) or, if an agonist is used, anti-androgen coverage begun before the agonist.
Option A: Option A is incorrect because the danger is the testosterone flare, not a failure of the depot to release drug; depots do achieve castration over 3 to 4 weeks, but the acute risk is the early surge, not delayed suppression.
Option B: Option B is incorrect because the flare risk is hormonally mediated (a testosterone surge stimulating tumor activity), not a direct drug stimulation of osteoblastic metastases independent of hormones.
Option D: Option D is incorrect because agonists do not lower testosterone rapidly — they raise it initially and lower it only over weeks; acute vertebral collapse from rapid androgen withdrawal is not the mechanism of concern.
Option E: Option E is incorrect because GnRH agonists do not cause complement-mediated anaphylaxis; that risk was associated with the antagonist abarelix, and it is not related to PSA level or tumor burden.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. The team agrees that the testosterone flare must be avoided and that rapid testosterone suppression is needed given the impending cord compression. They elect to use a GnRH antagonist. Which of the following best describes the agent and the expected pharmacodynamic response?
A) Degarelix, given as a subcutaneous loading dose of 240 mg (two 120 mg injections on day 1) followed by monthly 80 mg maintenance, competitively and reversibly blocks the GnRH receptor without any initial activation, achieving castrate testosterone (below 50 ng/dL) in more than 96% of patients within about 3 days and producing no testosterone flare
B) Degarelix is a partial agonist that produces low-level receptor activation; testosterone falls gradually over 3 to 4 weeks without a surge, similar in timing to a depot agonist
C) Degarelix irreversibly blocks the GnRH receptor by covalent binding, permanently inactivating it so that a single injection suppresses testosterone for the patient's lifetime
D) Degarelix blocks peripheral androgen receptors rather than the pituitary GnRH receptor, so serum testosterone remains elevated while tumor stimulation is prevented
E) Degarelix acts on FSH receptors at the pituitary, leaving LH secretion intact, which is why it must be combined with an anti-androgen to achieve castrate testosterone
ANSWER: A
Rationale:
Degarelix is a competitive, reversible GnRH receptor antagonist. Given as a subcutaneous loading dose of 240 mg (two 120 mg injections on day 1) followed by monthly 80 mg maintenance doses, it blocks the GnRH receptor on pituitary gonadotrophs from the first dose, immediately suppressing LH and FSH with no initial receptor activation. It achieves castrate testosterone (below 50 ng/dL) in more than 96% of patients within about 3 days and produces no testosterone flare — exactly what this patient with impending cord compression requires.
Option B: Option B is incorrect because degarelix is a full competitive antagonist, not a partial agonist; it produces no receptor activation, and testosterone falls within days, not gradually over 3 to 4 weeks like a depot agonist.
Option C: Option C is incorrect because degarelix binds reversibly, not covalently; it does not permanently inactivate the receptor, and its effect depends on continued dosing (monthly maintenance), not a single lifetime injection.
Option D: Option D is incorrect because degarelix acts at the pituitary GnRH receptor to suppress gonadotropins and lower testosterone; it does not work by blocking peripheral androgen receptors while leaving testosterone elevated.
Option E: Option E is incorrect because degarelix blocks the GnRH receptor (suppressing both LH and FSH), not FSH receptors selectively; it achieves castrate testosterone on its own and does not require an anti-androgen to do so.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. Three days after the degarelix loading dose his testosterone is 22 ng/dL, his pain is improving, and radiotherapy has begun. He is transitioned to monthly maintenance and his disease responds. Over the following year, the team monitors his testosterone to confirm ongoing castration. Which of the following best describes the appropriate castration target and the interpretation of a non-castrate result on therapy?
A) The castration target is a testosterone below 100 ng/dL; any value under 100 ng/dL is fully adequate and requires no further action, because outcomes are identical across the 50 to 100 ng/dL range
B) The castration target is irrelevant once PSA is undetectable; testosterone need not be monitored because PSA alone fully reflects the adequacy of androgen suppression
C) The castration target is a testosterone above 50 ng/dL, which confirms that the pituitary retains enough function to prevent oversuppression; values below 50 ng/dL indicate harmful oversuppression requiring dose reduction
D) The castration target is a testosterone below 50 ng/dL (with newer guidelines favoring below 20 ng/dL); a value rising above this threshold on therapy is non-castrate testosterone and should prompt evaluation for delivery or adherence problems and consideration of management changes, even if PSA is still low
E) The castration target is a testosterone below 50 ng/dL only during the first month; thereafter testosterone naturally rises into the normal range as the pituitary adapts, and this rise should not be treated
ANSWER: D
Rationale:
The accepted castration target is a serum testosterone below 50 ng/dL, with newer guidelines favoring a deeper target of below 20 ng/dL because outcomes appear better at lower levels. A testosterone rising above the castration threshold while on therapy constitutes non-castrate testosterone and should prompt evaluation — for delivery problems (injection technique, site issues), adherence, or end-of-dose escape — and consideration of management changes, even when PSA remains low, because failure of castration can precede biochemical progression.
Option A: Option A is incorrect because the castration target is below 50 ng/dL (or below 20 ng/dL by newer criteria), not below 100 ng/dL; values between 50 and 100 ng/dL are not adequately castrate, and outcomes are not identical across that range.
Option B: Option B is incorrect because testosterone monitoring is an essential part of confirming adequate suppression; PSA alone does not substitute, since non-castrate testosterone can occur and is clinically actionable.
Option C: Option C is incorrect because it inverts the target: castration requires testosterone below 50 ng/dL, and values below 50 ng/dL are the goal, not evidence of harmful oversuppression; there is no oversuppression problem requiring dose reduction in this context.
Option E: Option E is incorrect because the castration target applies throughout therapy, not only the first month; testosterone does not naturally rise into the normal range as the pituitary adapts during effective suppression, and a rise above target is abnormal and warrants evaluation.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. Eighteen months into continuous androgen deprivation therapy, he remains in remission. A surveillance DEXA shows that his lumbar spine T-score has declined from -0.9 at baseline to -1.8. He is otherwise asymptomatic and takes no bone-targeted medication. Which of the following is the most appropriate bone-health management?
A) No intervention is needed because bone mineral density loss during androgen deprivation therapy is clinically insignificant and never progresses to fracture
B) Ensure adequate calcium (about 1,000 to 1,200 mg daily) and vitamin D (about 800 to 1,000 IU daily), promote weight-bearing exercise, and — given the low T-score, ongoing testosterone suppression, and prolonged therapy — initiate a bone-protective agent such as zoledronic acid 4 mg intravenously every 12 months or denosumab 60 mg subcutaneously every 6 months
C) Begin low-dose testosterone supplementation to restore bone density, accepting the oncologic risk because bone protection takes priority
D) Discontinue androgen deprivation therapy entirely, since any decline in bone density mandates stopping treatment regardless of cancer status
E) Restrict calcium and vitamin D intake to avoid hypercalcemia, since androgen deprivation therapy already increases bone turnover and additional calcium would accelerate vascular calcification without benefiting bone
ANSWER: B
Rationale:
Bone mineral density (BMD) loss is the most clinically significant long-term adverse effect of androgen deprivation therapy (ADT), with BMD declining roughly 2 to 3% per year and fracture risk rising after about 12 months of therapy. The foundation of management is adequate calcium (about 1,000 to 1,200 mg daily) and vitamin D (about 800 to 1,000 IU daily) plus weight-bearing exercise. In a patient with a low T-score, ongoing testosterone suppression, and prolonged (more than 12 months) ADT, a bone-protective agent — zoledronic acid 4 mg intravenously every 12 months or denosumab 60 mg subcutaneously every 6 months — is indicated; denosumab has a strong evidence base for reducing fracture risk in men on ADT.
Option A: Option A is incorrect because ADT-related bone loss is clinically significant and can progress to fragility fractures; it is not a benign finding to be ignored.
Option C: Option C is incorrect because testosterone supplementation is contraindicated in prostate cancer, as it would stimulate tumor growth; bone protection is achieved with non-hormonal agents.
Option D: Option D is incorrect because a decline in BMD does not mandate stopping effective ADT; the appropriate response is to add bone-protective therapy while continuing cancer treatment.
Option E: Option E is incorrect because calcium and vitamin D should be ensured, not restricted, in men on ADT; adequate supplementation supports bone health, and restricting it would worsen, not prevent, bone loss.
5. [CASE 2 — QUESTION 1]
A 34-year-old woman with biopsy-confirmed endometriosis has moderate-to-severe pelvic pain inadequately controlled by NSAIDs and combined oral contraceptives. She has a maternal history of early osteoporosis and a baseline DEXA in the low-normal range. Her gynecologist plans to start the oral GnRH antagonist elagolix and must select a dose that balances pain control against bone safety. Which of the following best describes the dose-dependent pharmacodynamic profile of elagolix relevant to this decision?
A) Elagolix produces the same depth of estradiol suppression at every approved dose, so the choice between 150 mg once daily and 200 mg twice daily affects only the dosing frequency, not the degree of suppression or bone risk
B) Elagolix 150 mg once daily produces deeper estradiol suppression than 200 mg twice daily, so the once-daily dose carries greater bone risk and should be avoided in this patient
C) Elagolix achieves pain control only at the 200 mg twice-daily dose; the 150 mg once-daily dose has no meaningful effect on endometriosis pain and is used solely for cycle regulation
D) Elagolix suppresses estradiol independently of dose; the bone risk depends only on treatment duration, so any dose may be used for up to 24 months without difference in bone outcome
E) Elagolix produces dose-dependent suppression of the gonadal axis: the 150 mg once-daily dose gives partial estradiol suppression to early follicular phase levels (about 12 to 73 pg/mL) with moderate pain relief, preserved partial ovarian function, and attenuated bone loss (usable up to 24 months), whereas 200 mg twice daily gives near-complete suppression with greater pain relief but more bone loss and shorter permissible duration
ANSWER: E
Rationale:
Elagolix has a dose-dependent pharmacodynamic profile that is central to dose selection. The 150 mg once-daily dose produces partial estradiol suppression to approximately early follicular phase levels (about 12 to 73 pg/mL): it provides moderate pain relief while preserving some ovarian estradiol output, which attenuates bone mineral density (BMD) loss and permits use for up to 24 months. The 200 mg twice-daily dose produces near-complete suppression (estradiol below about 12 pg/mL, equivalent to surgical menopause): greater pain relief but more BMD loss and a shorter permissible duration without add-back. For a patient at elevated bone risk, the lower dose is attractive.
Option A: Option A is incorrect because elagolix does not produce the same suppression at every dose; the dose-dependent difference in estradiol suppression is its defining feature and directly affects bone risk.
Option B: Option B is incorrect because it inverts the relationship: 200 mg twice daily produces deeper suppression and greater bone risk, not the 150 mg once-daily dose.
Option C: Option C is incorrect because the 150 mg once-daily dose does provide clinically meaningful pain relief; it is not limited to cycle regulation.
Option D: Option D is incorrect because elagolix suppression is dose-dependent, not dose-independent, and bone risk scales with the depth of suppression, not duration alone. The two doses also differ in permissible duration.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient. After shared decision-making, she and her gynecologist elect to start elagolix 200 mg twice daily to maximize pain control, with a plan to add bone-protective add-back. Before starting, she is diagnosed with esophageal candidiasis, and the consulting team proposes oral ketoconazole. Which of the following is the most appropriate assessment of combining ketoconazole with the planned elagolix regimen?
A) Ketoconazole and elagolix do not interact, because elagolix is cleared primarily by renal excretion of unchanged drug; the antifungal can be added without modification
B) Ketoconazole is a strong CYP3A4 inhibitor and elagolix is a major CYP3A4 substrate, so co-administration substantially raises elagolix exposure; the elagolix 200 mg twice-daily dose is contraindicated with strong CYP3A4 inhibitors, and an alternative antifungal should be chosen or the elagolix plan reconsidered
C) Ketoconazole induces CYP3A4 and would lower elagolix exposure, reducing pain control; the elagolix dose should be increased during the antifungal course
D) The interaction is neutralized by the planned norethindrone acetate add-back, which alters elagolix metabolism and prevents any rise in elagolix concentration
E) Ketoconazole increases elagolix clearance by inducing intestinal P-glycoprotein, so the elagolix dose must be doubled during co-administration to maintain efficacy
ANSWER: B
Rationale:
Elagolix is metabolized primarily by CYP3A4, and ketoconazole is one of the most potent CYP3A4 inhibitors. Co-administration substantially increases elagolix plasma concentrations, and the elagolix 200 mg twice-daily dose is specifically contraindicated with strong CYP3A4 inhibitors because the resulting exposure can reach potentially harmful levels. The appropriate course is to select an alternative antifungal that does not strongly inhibit CYP3A4, or to reconsider the elagolix regimen.
Option A: Option A is incorrect because elagolix is not cleared primarily by renal excretion of unchanged drug; it undergoes extensive hepatic CYP3A4 metabolism, which is exactly why the ketoconazole interaction matters.
Option C: Option C is incorrect because ketoconazole inhibits, not induces, CYP3A4; it raises elagolix exposure, so increasing the dose would compound toxicity.
Option D: Option D is incorrect because add-back therapy with norethindrone acetate addresses hypoestrogenic adverse effects and does not alter elagolix metabolism or neutralize a CYP3A4-mediated increase in elagolix concentration.
Option E: Option E is incorrect because ketoconazole does not induce intestinal P-glycoprotein to increase elagolix clearance; the dominant, clinically relevant mechanism is strong CYP3A4 inhibition that raises elagolix exposure, making the 200 mg twice-daily dose contraindicated.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient. The candidiasis is treated with a non-interacting antifungal, and she begins elagolix 200 mg twice daily. Because of her bone-risk history, the gynecologist adds add-back therapy from the outset. Which of the following best describes the physiologic target and rationale for add-back therapy in this setting?
A) Add-back therapy (for example, norethindrone acetate 1 mg daily used with the 200 mg twice-daily regimen, or low-dose estrogen plus a progestin) aims to hold estradiol within approximately the 20 to 40 pg/mL window — above the bone-loss threshold yet below the threshold that stimulates endometriosis — protecting bone and reducing vasomotor symptoms while preserving pain control and permitting longer therapy
B) Add-back therapy aims to raise estradiol above 60 pg/mL, because only supraphysiologic estrogen levels can protect bone during deep GnRH-axis suppression
C) Add-back therapy aims to drive estradiol below 10 pg/mL to maximize endometriosis suppression; bone protection is achieved separately and is unrelated to the estradiol level
D) Add-back therapy works by blocking estrogen receptors on bone, so the specific estradiol level achieved is irrelevant to its bone-protective effect
E) Add-back therapy is contraindicated with the 200 mg twice-daily dose because adding any estrogen fully reverses the pain-control benefit of elagolix
ANSWER: A
Rationale:
Add-back therapy applies the estrogen threshold principle. Endometriosis implants are stimulated above approximately 20 pg/mL estradiol, while bone loss accelerates below approximately 30 to 40 pg/mL; these constraints define a therapeutic window of roughly 20 to 40 pg/mL. Add-back (for example, norethindrone acetate 1 mg daily with the elagolix 200 mg twice-daily regimen, or low-dose estrogen plus a progestin) is dosed to hold estradiol in this window — above the bone-loss threshold to protect the skeleton and reduce hot flashes, but below the implant-stimulation threshold to maintain disease control. Appropriately dosed add-back preserves pain control and permits longer therapy than the higher dose would otherwise allow.
Option B: Option B is incorrect because raising estradiol above 60 pg/mL would exceed the implant-stimulation threshold and risk reactivating the endometriosis; the target is the 20 to 40 pg/mL window, not supraphysiologic levels.
Option C: Option C is incorrect because driving estradiol below 10 pg/mL would worsen bone loss; bone protection is directly related to keeping estradiol above the bone-loss threshold, not separate from the estradiol level.
Option D: Option D is incorrect because add-back works by providing a controlled level of circulating estrogen within the therapeutic window, not by blocking estrogen receptors on bone; the estradiol level achieved is central to its effect.
Option E: Option E is incorrect because appropriately dosed add-back does not reverse elagolix's pain-control benefit; it is specifically designed to be compatible with ongoing disease suppression while protecting bone.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient. She tolerates elagolix 200 mg twice daily with add-back well, and her pain is substantially improved. At a follow-up visit, she asks how long she can stay on this therapy and what monitoring she needs. Which of the following best describes the duration limits and monitoring for her regimen?
A) The 200 mg twice-daily dose may be continued indefinitely without add-back and requires no bone monitoring, because elagolix does not affect bone mineral density at any dose
B) No duration limit or monitoring applies to elagolix because it is an oral agent; duration limits apply only to injectable depot GnRH agonists
C) Elagolix 200 mg twice daily is limited to about 6 months without add-back but may be extended to about 12 months with add-back; the lower 150 mg once-daily dose may be used up to 24 months; bone mineral density should be monitored, and hypoestrogenic symptoms and mood changes should be assessed during therapy
D) Elagolix has no maximum duration at the 200 mg twice-daily dose as long as add-back is used, and bone monitoring is unnecessary once add-back is started because add-back fully eliminates all bone loss
E) Elagolix at any dose must be stopped at 3 months regardless of add-back, because hypoestrogenic bone loss becomes irreversible after 3 months of therapy
ANSWER: C
Rationale:
Elagolix duration is dose-dependent and tied to hypoestrogenic bone risk. The 200 mg twice-daily dose is limited to about 6 months without add-back therapy but may be extended to about 12 months with add-back. The lower 150 mg once-daily dose, which produces only partial suppression, may be used for up to 24 months. Across these regimens, bone mineral density (BMD) should be monitored, and hypoestrogenic symptoms (vasomotor symptoms) and mood changes should be assessed during therapy.
Option A: Option A is incorrect because the 200 mg twice-daily dose is not used indefinitely without add-back and does affect BMD; bone monitoring is appropriate, contrary to the claim.
Option B: Option B is incorrect because duration limits and monitoring do apply to elagolix; they are not restricted to injectable depot agonists.
Option D: Option D is incorrect because even with add-back the 200 mg twice-daily dose has a duration limit (about 12 months), and add-back substantially attenuates but does not entirely eliminate bone loss, so monitoring remains appropriate.
Option E: Option E is incorrect because elagolix is not required to stop at 3 months, and hypoestrogenic bone loss is not irreversible after 3 months; the actual duration limits are about 6 months without add-back and about 12 months with add-back for the higher dose, and up to 24 months for the lower dose.
9. [CASE 3 — QUESTION 1]
A 7-year-old girl is evaluated for breast development and pubic hair that began at age 6.5, with a growth spurt and a bone age advanced 2 years beyond her chronological age. Pelvic ultrasound shows ovarian follicular activity, and a GnRH stimulation test confirms central precocious puberty (CPP) with a pubertal LH response. The pediatric endocrinologist plans GnRH agonist depot therapy. Which of the following best describes the standard initial pharmacologic regimen for central precocious puberty?
A) Continuous low-dose pulsatile GnRH by pump every 90 minutes, to gently stimulate the pituitary and allow puberty to proceed at a controlled pace
B) A GnRH antagonist such as degarelix given monthly, because antagonists are the standard first-line agents for central precocious puberty owing to immediate suppression without a flare
C) An anti-androgen such as bicalutamide as monotherapy, to block the peripheral effects of sex steroids while leaving the hypothalamic-pituitary-gonadal axis intact
D) Leuprolide depot (Lupron Depot-Pediatric) at 0.3 mg/kg (minimum 7.5 mg) intramuscularly every 4 weeks, which produces continuous GnRH receptor occupancy and downregulation to suppress the hypothalamic-pituitary-gonadal axis and halt pubertal progression; longer-acting 3-month formulations and an annual histrelin implant are alternatives
E) High-dose estrogen therapy to accelerate epiphyseal fusion and shorten the remaining growth period, thereby limiting the height discrepancy
ANSWER: D
Rationale:
Central precocious puberty (CPP) is treated with GnRH agonist depot therapy to halt pubertal progression and preserve final adult height. The standard initial regimen is leuprolide depot (Lupron Depot-Pediatric) at 0.3 mg/kg (with a minimum dose of 7.5 mg) intramuscularly every 4 weeks. Continuous, non-pulsatile GnRH receptor occupancy desensitizes and downregulates pituitary gonadotrophs, suppressing LH and FSH and thereby halting pubertal progression. Longer-acting 3-month leuprolide formulations and an annual histrelin subcutaneous implant are accepted alternatives.
Option A: Option A is incorrect because pulsatile GnRH stimulation maintains gonadotropin secretion and would drive, not suppress, puberty; pulsatile therapy is used to induce fertility in hypogonadotropic hypogonadism, the opposite of the goal in CPP.
Option B: Option B is incorrect because GnRH antagonists are not the standard first-line therapy for CPP; GnRH agonist depots are the established standard, and the transient initial agonist surge is clinically manageable in this setting.
Option C: Option C is incorrect because anti-androgen monotherapy does not suppress the activated hypothalamic-pituitary-gonadal axis driving central precocious puberty; CPP requires central suppression with a GnRH agonist, not peripheral androgen blockade.
Option E: Option E is incorrect because high-dose estrogen would accelerate epiphyseal fusion and worsen the loss of final height; the goal of therapy is to slow skeletal maturation by suppressing sex steroids, not to hasten fusion.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient. She is started on leuprolide depot 7.5 mg intramuscularly every 4 weeks. After 6 months, her breast development has continued to progress and her growth velocity remains accelerated. A GnRH stimulation test shows a stimulated LH peak of 5.0 IU/L (IU per liter) at 40 minutes. Which of the following best interprets this result and indicates the appropriate next step?
A) The stimulated LH of 5.0 IU/L confirms adequate suppression; the continued progression reflects peripheral precocious puberty, and the leuprolide should be stopped
B) The stimulated LH of 5.0 IU/L is above the target of below 2 IU/L that defines adequate hypothalamic-pituitary-gonadal axis suppression; together with the continued clinical progression, this indicates inadequate suppression, and the dose should be increased or the dosing interval shortened, followed by repeat confirmation
C) The stimulated LH of 5.0 IU/L confirms adequate suppression, and continued breast development with accelerated growth is expected in the first year and requires no change
D) The result indicates oversuppression of the axis, and the leuprolide dose should be reduced to permit controlled pubertal progression
E) GnRH stimulation testing cannot assess suppression adequacy in children on depot agonists; an unstimulated random LH should be used instead, and no change should be made on the basis of this result
ANSWER: B
Rationale:
In central precocious puberty, adequacy of hypothalamic-pituitary-gonadal (HPG) axis suppression on depot GnRH agonist therapy is confirmed by a stimulated LH peak below 2 IU/L (IU per liter) after GnRH or GnRH agonist stimulation, typically at 30 to 60 minutes. This patient's stimulated LH of 5.0 IU/L is above the threshold, indicating inadequate suppression — and the biochemical finding is corroborated clinically by continued breast development and persistently accelerated growth. The appropriate response is to intensify therapy by increasing the dose or shortening the dosing interval, then reconfirm adequate suppression with repeat stimulation testing.
Option A: Option A is incorrect because a stimulated LH of 5.0 IU/L does not confirm adequate suppression (target is below 2 IU/L), and the picture is consistent with inadequately suppressed central precocious puberty, not peripheral precocious puberty; stopping leuprolide would worsen the situation.
Option C: Option C is incorrect because a stimulated LH of 5.0 IU/L is above the suppression target, and continued progression signals treatment failure, not an expected and acceptable finding.
Option D: Option D is incorrect because a stimulated LH of 5.0 IU/L reflects insufficient, not excessive, suppression; reducing the dose would worsen control and accelerate pubertal progression.
Option E: Option E is incorrect because GnRH (or GnRH agonist) stimulation testing is the standard, valid method to confirm suppression adequacy, with a stimulated peak LH below 2 IU/L as the accepted criterion.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient. After the dose is increased, repeat stimulation testing confirms a stimulated LH below 2 IU/L, breast development stabilizes, and her growth velocity normalizes to an age-appropriate rate. Her parents, noting she is currently the tallest child in her class, ask how suppressing puberty will help her be taller as an adult. Which of the following best explains how GnRH agonist therapy preserves final adult height?
A) GnRH agonist therapy increases pituitary growth hormone secretion, directly stimulating long-bone growth and adding adult height
B) GnRH agonist therapy preserves height by suppressing adrenal androgen production, which is the sole driver of both the growth spurt and epiphyseal closure in precocious puberty
C) GnRH agonist therapy directly prevents epiphyseal growth-plate fusion through a local action on chondrocytes, independent of any effect on sex steroids
D) Her current tall stature guarantees a tall adult height; the therapy does not actually affect adult height and is given only to address the psychosocial effects of early puberty
E) In precocious puberty, premature sex steroid exposure accelerates linear growth now but also rapidly advances skeletal maturation, causing early epiphyseal fusion that truncates the growth period; by suppressing the hypothalamic-pituitary-gonadal axis and lowering sex steroids, GnRH agonist therapy halts the premature advance of bone age and extends the time available for growth before the plates fuse, preserving final adult height
ANSWER: E
Rationale:
The explanation links sex steroid suppression to growth-plate physiology. In central precocious puberty, premature sex steroid exposure accelerates linear growth in the short term (making the child temporarily tall for age) but simultaneously and rapidly advances skeletal maturation (bone age), driving early fusion of the epiphyseal growth plates. Because growth stops at fusion, this premature advancement truncates the total growth period and ultimately compromises final adult height. GnRH agonist therapy suppresses the hypothalamic-pituitary-gonadal (HPG) axis and lowers sex steroids, halting the premature advance of bone age and extending the time available for skeletal growth before the plates fuse — thereby preserving final adult height even though the child appears tall now.
Option A: Option A is incorrect because GnRH agonist therapy does not preserve height by increasing growth hormone secretion to directly stimulate bone growth; it works by halting premature skeletal maturation.
Option B: Option B is incorrect because the principal driver of the growth acceleration and bone-age advancement in central precocious puberty is gonadal sex steroid production downstream of activated gonadotropins, not adrenal androgens as the sole driver; GnRH agonists act on the gonadal axis.
Option C: Option C is incorrect because GnRH agonists do not act directly on chondrocytes to prevent fusion; they preserve growth potential indirectly by lowering sex steroids and slowing bone-age advancement.
Option D: Option D is incorrect because the therapy does meaningfully preserve final adult height by preventing premature epiphyseal fusion; current tall stature does not guarantee tall adult height, since untreated precocious puberty typically results in reduced adult height.
12. [CASE 3 — QUESTION 4]
Continuing with the same patient. The family finds the every-4-week intramuscular injections difficult to keep up with and asks whether a longer-acting option exists that would reduce the frequency of visits while maintaining suppression. Which of the following best describes an appropriate alternative GnRH agonist delivery system for central precocious puberty?
A) Histrelin acetate subcutaneous implant (Supprelin LA), placed under the skin and replaced about once yearly, provides continuous agonist delivery that maintains consistent LH suppression with the convenience of annual replacement, making it a suitable longer-acting alternative to monthly injections
B) A GnRH antagonist oral tablet taken once daily, because oral antagonists are approved for central precocious puberty and avoid injections entirely
C) Pulsatile GnRH by pump, which reduces visit frequency while maintaining suppression because pulsatile delivery downregulates the receptor more durably than continuous delivery
D) A single intramuscular leuprolide injection that provides lifelong suppression, eliminating the need for any further dosing throughout childhood
E) Intranasal buserelin given once weekly, which is the standard long-acting option for central precocious puberty in children and provides the most consistent suppression of all available formulations
ANSWER: A
Rationale:
The histrelin acetate subcutaneous implant (Supprelin LA) is an established longer-acting alternative for central precocious puberty. The implant is placed under the skin and replaced approximately once yearly; it provides continuous GnRH agonist delivery that maintains consistent LH suppression with the convenience of annual replacement, which reduces the burden of frequent injections. Along with 3-month depot leuprolide formulations, it is an accepted alternative to the every-4-week regimen.
Option B: Option B is incorrect because oral GnRH antagonist tablets are not approved or standard for central precocious puberty; the established options are GnRH agonist depots and the histrelin implant.
Option C: Option C is incorrect because pulsatile GnRH delivery maintains gonadotropin secretion and would drive puberty rather than suppress it; only continuous delivery produces the downregulation needed for suppression.
Option D: Option D is incorrect because no single leuprolide injection provides lifelong suppression; depot agonist therapy requires ongoing dosing, and suppression is reversible upon discontinuation.
Option E: Option E is incorrect because intranasal buserelin is not a once-weekly long-acting standard for central precocious puberty; intranasal formulations require frequent daily dosing and are not the most consistent option, whereas the histrelin implant provides reliable continuous delivery.
13. [CASE 4 — QUESTION 1]
A 27-year-old man with anosmia, absent puberty, low LH, low FSH, low testosterone, and a structurally normal pituitary on imaging is diagnosed with Kallmann syndrome, a form of isolated hypogonadotropic hypogonadism. He is referred to discuss future fertility. The endocrinologist explains that his pituitary is capable of normal function and that a specific pattern of GnRH delivery can restore his reproductive axis. Which of the following best explains why pulsatile, rather than continuous, GnRH delivery is required to restore the axis?
A) Continuous GnRH delivery restores the axis because steady receptor occupancy provides the strongest and most sustained gonadotropin stimulation, while pulsatile delivery is too intermittent to be effective
B) Pulsatile and continuous GnRH delivery are equivalent in this setting; the choice is based only on patient convenience, not on any difference in receptor signaling outcome
C) Pulsatile GnRH delivery, mimicking physiologic hypothalamic secretion, maintains GnRH receptor responsiveness between pulses and drives normal LH and FSH secretion, whereas continuous GnRH receptor occupancy causes desensitization and downregulation that suppress gonadotropins — so only the pulsatile pattern restores the reproductive axis
D) Pulsatile GnRH delivery works because each pulse reaches a higher peak concentration that overcomes a fixed receptor threshold, whereas continuous delivery never reaches that threshold
E) Continuous GnRH delivery is required because the pituitary in Kallmann syndrome responds only to uninterrupted stimulation; pulsatile delivery fails because the gaps between pulses allow the axis to shut down
ANSWER: C
Rationale:
The reproductive axis decodes the temporal pattern of GnRH receptor stimulation. Physiologic, pulsatile GnRH delivery — mimicking hypothalamic secretion — maintains receptor responsiveness between pulses and drives normal LH and FSH secretion from the intact pituitary, restoring gonadal function. Continuous, non-pulsatile receptor occupancy, by contrast, causes desensitization and downregulation that suppress gonadotropins (the mechanism exploited therapeutically by GnRH agonist depots). In Kallmann syndrome the pituitary is intact, so providing GnRH in the correct pulsatile pattern restores the axis, whereas continuous delivery would suppress it.
Option A: Option A is incorrect because continuous delivery suppresses rather than restores the axis through receptor desensitization and downregulation; pulsatile delivery is effective, not too intermittent.
Option B: Option B is incorrect because pulsatile and continuous delivery are not equivalent; they produce opposite outcomes (stimulation versus suppression), so the choice is mechanistic, not merely convenience.
Option D: Option D is incorrect because the key variable is the pulsatile pattern that maintains receptor responsiveness, not a higher peak concentration overcoming a fixed threshold; continuous high-level occupancy actually suppresses the axis.
Option E: Option E is incorrect because continuous delivery suppresses the axis; the gaps between pulses are precisely what preserve receptor responsiveness and prevent downregulation, so pulsatile delivery succeeds rather than fails.
14. [CASE 4 — QUESTION 2]
Continuing with the same patient. For several years he has used testosterone gel, which restored his libido and energy. He and his partner now wish to conceive. He is surprised to learn that his current treatment will not permit fertility. Which of the following is the most appropriate change in management to restore his fertility?
A) Increase the testosterone gel dose, since higher systemic testosterone will more effectively drive spermatogenesis in hypogonadotropic men
B) Continue testosterone gel and add a GnRH agonist depot, because combined therapy maximizes intratesticular androgen production needed for spermatogenesis
C) Begin a continuous GnRH infusion, because steady receptor occupancy provides the most reliable stimulation of pituitary gonadotropin output for fertility
D) Begin a GnRH antagonist such as degarelix to relieve receptor desensitization and allow the pituitary to recover gonadotropin secretion
E) Discontinue testosterone replacement and begin pulsatile GnRH therapy via a portable pump delivering GnRH every 60 to 120 minutes (or alternatively exogenous gonadotropin therapy), because physiologic pulsatile stimulation of the intact pituitary restores LH and FSH secretion and intratesticular testosterone, inducing spermatogenesis, whereas exogenous testosterone suppresses gonadotropins and spermatogenesis through negative feedback
ANSWER: E
Rationale:
Spermatogenesis depends on very high intratesticular testosterone generated by LH-stimulated Leydig cells together with FSH support of Sertoli cells. Exogenous testosterone raises serum testosterone (relieving fatigue and restoring libido) but does not raise intratesticular testosterone, and it suppresses pituitary LH and FSH through negative feedback — shutting down the gonadotropin drive needed for sperm production. The fertility-restoring strategies are pulsatile GnRH therapy (a portable pump delivering GnRH every 60 to 120 minutes to mimic physiologic secretion, stimulating LH and FSH and raising intratesticular testosterone) or exogenous gonadotropin therapy. Critically, exogenous testosterone must be discontinued. Pulsatile GnRH therapy induces spermatogenesis adequate for conception in roughly 75 to 80% of treated hypogonadotropic men.
Option A: Option A is incorrect because raising systemic testosterone does not drive spermatogenesis; sperm production requires high intratesticular testosterone from gonadotropin stimulation, and exogenous testosterone suppresses that drive.
Option B: Option B is incorrect because continuing testosterone suppresses gonadotropins, and a GnRH agonist depot produces continuous occupancy that downregulates the receptor and further suppresses the axis — the opposite of what is needed.
Option C: Option C is incorrect because continuous GnRH stimulation causes receptor downregulation and suppression of gonadotropins; only pulsatile delivery maintains gonadotropin secretion and supports fertility.
Option D: Option D is incorrect because degarelix is a GnRH antagonist that blocks the receptor and suppresses gonadotropins; it would deepen the deficiency, not restore fertility.
15. [CASE 4 — QUESTION 3]
Continuing with the same patient. He discontinues testosterone and begins pulsatile GnRH therapy via a portable subcutaneous pump. He asks how the pump is programmed and what outcome he can realistically expect. Which of the following best describes the typical pump parameters and expected fertility outcome?
A) The pump delivers a single large GnRH bolus once daily; spermatogenesis adequate for conception is achieved in fewer than 10% of treated men, so the approach is generally reserved for research settings
B) The pump delivers small GnRH doses (about 2.5 to 20 mcg per pulse) subcutaneously or intravenously every 60 to 120 minutes to mimic physiologic hypothalamic secretion; with monitoring of hormone levels and gonadal response, spermatogenesis adequate for natural conception is achieved in roughly 75 to 80% of treated hypogonadotropic men
C) The pump delivers continuous GnRH at a fixed rate without pulses; spermatogenesis is achieved in nearly all men within 2 weeks because steady stimulation maximizes gonadotropin output
D) The pump delivers GnRH pulses every 12 hours; fertility outcomes are equivalent to testosterone therapy because both ultimately raise serum testosterone to the same degree
E) The pump delivers high-dose GnRH every few minutes to rapidly saturate the receptor; this produces immediate spermatogenesis but requires hospitalization due to the risk of ovarian hyperstimulation
ANSWER: B
Rationale:
Pulsatile GnRH pump therapy mimics physiologic hypothalamic secretion. A portable pump delivers small GnRH doses (about 2.5 to 20 mcg per pulse) subcutaneously or intravenously at intervals of approximately 60 to 120 minutes. With education, device maintenance, and monitoring of hormone levels and gonadal response, this restores pituitary LH and FSH secretion and supports spermatogenesis, achieving sperm production adequate for natural conception in roughly 75 to 80% of treated hypogonadotropic men.
Option A: Option A is incorrect because the pump delivers frequent small pulses (every 60 to 120 minutes), not a single large daily bolus, and success rates are roughly 75 to 80%, not under 10%; this is an established clinical therapy, not merely a research approach.
Option C: Option C is incorrect because continuous GnRH delivery would desensitize and downregulate the receptor and suppress gonadotropins, not maximize output; pulsatile, not continuous, delivery is required, and spermatogenesis develops over months, not 2 weeks.
Option D: Option D is incorrect because pulse intervals are about 60 to 120 minutes, not every 12 hours, and fertility outcomes are not equivalent to testosterone therapy — testosterone suppresses spermatogenesis, whereas pulsatile GnRH restores it.
Option E: Option E is incorrect because the pulse interval is about 60 to 120 minutes, not every few minutes, and ovarian hyperstimulation is not relevant to a male patient; the description conflates unrelated concepts.
16. [CASE 4 — QUESTION 4]
Continuing with the same patient. His sister also has isolated hypogonadotropic hypogonadism and is being counseled about ovulation induction for her own fertility. The endocrinologist contrasts pulsatile GnRH therapy with exogenous gonadotropin therapy in women with this condition. Which of the following best describes a key advantage of pulsatile GnRH therapy over exogenous gonadotropins in hypogonadotropic women?
A) Pulsatile GnRH therapy bypasses the pituitary entirely and acts directly on the ovary, which is why it produces more reliable ovulation than gonadotropins in women with pituitary failure
B) Pulsatile GnRH therapy guarantees twin or higher-order pregnancies, which is considered advantageous because it shortens the time to complete a desired family
C) Pulsatile GnRH therapy requires no monitoring of any kind, unlike gonadotropin therapy, because the pump automatically prevents any excessive ovarian response
D) Pulsatile GnRH therapy drives the pituitary to secrete LH and FSH in a physiologic, self-regulated pattern that is subject to normal feedback, which tends to produce more physiologic follicular development and a lower risk of the supraphysiologic gonadotropin levels and multiple follicular development that complicate exogenous gonadotropin therapy
E) Pulsatile GnRH therapy is preferred only because it is less expensive than gonadotropins; there is no physiologic difference in how the two approaches stimulate the ovary
ANSWER: D
Rationale:
In hypogonadotropic women with an intact pituitary, pulsatile GnRH therapy stimulates the pituitary to secrete LH and FSH in a physiologic, self-regulated pattern that remains subject to normal feedback mechanisms. This tends to produce more physiologic follicular development and reduces the risk of the supraphysiologic gonadotropin levels and multiple follicular development that can complicate exogenous gonadotropin therapy (where FSH is administered directly and bypasses pituitary feedback regulation). This is a recognized advantage of restoring the axis at the level of the pituitary rather than supplying gonadotropins directly.
Option A: Option A is incorrect because pulsatile GnRH therapy acts on the pituitary to stimulate LH and FSH secretion — it does not bypass the pituitary to act directly on the ovary; its advantage stems from engaging physiologic pituitary feedback, which requires a functioning pituitary.
Option B: Option B is incorrect because producing multiple follicular development and multiple gestations is a risk to be avoided, not an advantage; pulsatile GnRH therapy reduces, rather than guarantees, multiple pregnancies.
Option C: Option C is incorrect because pulsatile GnRH therapy still requires monitoring of hormone levels and gonadal response; the pump does not automatically eliminate the need for surveillance.
Option E: Option E is incorrect because there is a genuine physiologic difference between the two approaches — pulsatile GnRH engages normal pituitary feedback regulation, whereas exogenous gonadotropins bypass it — so the preference is not merely about cost.
17. [CASE 5 — QUESTION 1]
A 75-year-old man with newly diagnosed metastatic hormone-sensitive prostate cancer requires androgen deprivation therapy. His history includes a myocardial infarction 3 months ago, heart failure with a left ventricular ejection fraction of 35%, and a prior ischemic stroke. His cardiologist asks the oncology team to choose the androgen deprivation agent with the most favorable cardiovascular profile. Which of the following is best supported by the available evidence, and why?
A) Oral relugolix, because in the randomized HERO trial comparing relugolix with leuprolide, relugolix achieved effective castration and was associated with a substantially lower rate of major adverse cardiovascular events, supporting its preference in men with established cardiovascular disease
B) Leuprolide depot, because long-acting agonist depots provide steadier suppression that lowers cardiovascular events compared with oral agents in men with established heart disease
C) Bicalutamide monotherapy, because avoiding pituitary suppression keeps testosterone normal and spares the cardiovascular system the harms of hypogonadism while still controlling the cancer
D) Any GnRH agonist depot, because randomized evidence shows the specific agent has no influence on cardiovascular outcomes, which depend solely on the depth of testosterone suppression
E) Goserelin implant, because its subcutaneous route avoids the cardiovascular risk associated with intramuscular depot agonists
ANSWER: A
Rationale:
This patient has multiple high-risk cardiovascular features — recent myocardial infarction, heart failure with reduced ejection fraction, and prior stroke — so the cardiovascular profile of the agent matters. In the randomized HERO trial comparing oral relugolix with leuprolide in advanced prostate cancer, relugolix achieved effective, sustained castration and was associated with a substantially lower rate of major adverse cardiovascular events (MACE) than leuprolide. The cardiovascular advantage is attributed to relugolix's faster testosterone recovery kinetics and avoidance of some sustained agonist-associated metabolic effects. Applying this evidence, oral relugolix is the best-supported choice.
Option B: Option B is incorrect because long-acting agonist depots are not shown to lower cardiovascular events relative to antagonists; if anything, agonists are associated with greater cardiovascular risk than antagonists in high-risk patients.
Option C: Option C is incorrect because bicalutamide monotherapy does not provide adequate suppression for metastatic prostate cancer and is not appropriate primary therapy; it tends to raise serum testosterone and is not a cardiovascular risk-reduction strategy.
Option D: Option D is incorrect because the choice of agent does influence cardiovascular outcomes; agonists and antagonists are not equivalent despite producing similar castrate testosterone, as shown by the MACE difference in the HERO trial.
Option E: Option E is incorrect because goserelin is a GnRH agonist and its subcutaneous route does not confer a cardiovascular advantage; the relevant comparison is the antagonist relugolix versus the agonist leuprolide, not the injection route.
18. [CASE 5 — QUESTION 2]
Continuing with the same patient. He is started on oral relugolix 120 mg once daily and tolerates it well. Several months later he develops recurrent atrial fibrillation, and a covering physician proposes starting amiodarone for rhythm control. The oncology pharmacist is consulted. Which of the following best describes the relevant drug interaction and the appropriate response?
A) Amiodarone induces CYP3A4 and would accelerate relugolix metabolism, lowering its levels and risking loss of testosterone suppression; the relugolix dose should be doubled while amiodarone is used
B) Amiodarone displaces relugolix from plasma protein binding sites, transiently raising free relugolix; no action is needed because the effect is brief and self-limited
C) Amiodarone is a strong P-glycoprotein inhibitor and relugolix is a P-glycoprotein substrate, so co-administration can increase relugolix exposure substantially (up to about 4-fold); the combination should be avoided where possible, relugolix managed per labeling, and an alternative rhythm- or rate-control strategy that does not strongly inhibit P-glycoprotein considered
D) Amiodarone and relugolix do not interact, because relugolix is a major CYP3A4 substrate and amiodarone affects only P-glycoprotein; the two pathways never overlap, so the antiarrhythmic can be added freely
E) Relugolix should be discontinued entirely and permanently, because no antiarrhythmic agent can ever be safely co-administered with a GnRH antagonist
ANSWER: C
Rationale:
Relugolix is a substrate of P-glycoprotein (P-gp), and its disposition is governed by P-gp-mediated transport rather than by CYP3A4 metabolism. Amiodarone is a strong P-gp inhibitor. Co-administration reduces P-gp-mediated efflux of relugolix and can increase relugolix exposure substantially (up to about 4-fold), raising the risk of adverse effects. The appropriate response is to avoid the combination where possible, manage relugolix per its labeling, and consider an alternative rhythm- or rate-control strategy (for example, a beta-blocker) that does not strongly inhibit P-gp.
Option A: Option A is incorrect because amiodarone inhibits rather than induces the relevant pathway, and relugolix is not a major CYP3A4 substrate; doubling the dose would be mechanistically wrong and dangerous, since exposure rises rather than falls.
Option B: Option B is incorrect because the interaction is transporter-mediated (P-gp inhibition increasing exposure), not a brief plasma protein binding displacement; it is clinically significant and not self-limited.
Option D: Option D is incorrect because relugolix is a P-gp substrate, so amiodarone's P-gp inhibition does interact with it; the claim that the pathways never overlap is wrong.
Option E: Option E is incorrect because relugolix does not need to be permanently discontinued; the interaction is avoided by selecting an antiarrhythmic that does not strongly inhibit P-gp, allowing relugolix to continue.
19. [CASE 5 — QUESTION 3]
Continuing with the same patient. After the P-glycoprotein interaction is recognized, the team selects a rate-control strategy that avoids strong P-glycoprotein inhibition. However, the patient remains on relugolix and is also noted to have a baseline QTc of 470 ms. The team considers the cumulative effect of androgen deprivation therapy on the QT interval. Which of the following best describes the QT-related risk and appropriate management?
A) Androgen deprivation therapy has no effect on the QT interval; therefore the only QT consideration is the choice of antiarrhythmic, and no ECG monitoring related to the relugolix is needed
B) Androgen deprivation therapy prolongs the QTc through testosterone suppression, which is additive to the effects of any concurrent QT-prolonging drugs; with a baseline QTc of 470 ms, a baseline ECG, review of QT-prolonging medications, and repeat ECG after any change are appropriate, with cardiology input given his cardiac history
C) The QT-prolonging effect of androgen deprivation therapy is limited to the agonist class; because relugolix is an antagonist, it does not prolong the QTc and no QT monitoring is required
D) A baseline QTc of 470 ms is well within normal limits and requires no attention regardless of androgen deprivation therapy or co-medications
E) The QT risk arises solely from a direct effect of the relugolix molecule on cardiac ion channels, independent of testosterone; switching to a GnRH agonist would eliminate the QT concern entirely
ANSWER: B
Rationale:
Androgen deprivation therapy (ADT)-induced testosterone suppression prolongs the cardiac action potential and increases the corrected QT interval (QTc), and this effect is additive to that of any concurrent QT-prolonging drugs. This patient has a baseline QTc of 470 ms (already prolonged above the typical upper limit of about 440 ms in men) and significant cardiac disease. Appropriate management includes a baseline ECG, review and possible modification of QT-prolonging medications, repeat ECG after any relevant change, and cardiology input given his history. Patients with a baseline QTc above 500 ms or congenital long QT syndrome should not receive GnRH analogs without cardiology input.
Option A: Option A is incorrect because ADT does prolong the QT interval through testosterone suppression, so QT monitoring is relevant, not limited to the antiarrhythmic choice.
Option C: Option C is incorrect because the QT-prolonging effect of GnRH analogs is mediated by testosterone suppression and is a class effect shared by antagonists and agonists; relugolix suppresses testosterone and therefore also prolongs the QTc.
Option D: Option D is incorrect because a baseline QTc of 470 ms is prolonged, not within normal limits, and warrants attention, especially with cardiac comorbidity.
Option E: Option E is incorrect because the QT effect is mediated by testosterone suppression, a class effect, not by a direct relugolix effect on cardiac ion channels; switching to a GnRH agonist would not eliminate the concern, since agonists also suppress testosterone.
20. [CASE 5 — QUESTION 4]
Continuing with the same patient. His disease responds well, and after a planned course of androgen deprivation his oncologist considers discontinuing therapy. The patient asks how quickly his testosterone might recover compared with a friend who was on a long-acting injectable agonist. Which of the following best explains the recovery kinetics of oral relugolix and the pharmacologic basis for any difference?
A) Relugolix and long-acting depot agonists produce identical testosterone recovery kinetics, because recovery depends only on the hypothalamus and is independent of the drug's half-life or formulation
B) Relugolix produces slower testosterone recovery than depot agonists, because oral antagonists bind the receptor irreversibly and must be cleared by hepatic regeneration of new receptors over many months
C) Relugolix recovery is unpredictable and unrelated to its pharmacokinetics; testosterone may remain suppressed for years after stopping, similar to a depot agonist, owing to permanent gonadotroph downregulation
D) Relugolix produces faster recovery only because it is taken orally; the route of administration, not the half-life, determines how quickly testosterone returns after discontinuation
E) Relugolix has a relatively short plasma half-life (about 25 hours), so after discontinuation the drug is cleared quickly and the reversibly blocked GnRH receptors are rapidly freed, allowing testosterone to recover over weeks — substantially faster than after a long-acting depot agonist, whose sustained drug release continues to suppress the axis for months
ANSWER: E
Rationale:
Relugolix has a relatively short plasma half-life (about 25 hours) and acts as a reversible competitive GnRH receptor antagonist. After discontinuation, the drug is cleared quickly and the reversibly blocked receptors are rapidly freed, so the hypothalamic-pituitary-gonadal axis resumes function and testosterone recovers over weeks. This is substantially faster than recovery after a long-acting depot agonist, whose sustained drug release continues to occupy and downregulate the receptor for months, delaying testosterone recovery. This faster recovery is also one of the factors contributing to relugolix's more favorable cardiovascular profile.
Option A: Option A is incorrect because recovery kinetics are not identical; they depend strongly on the drug's half-life and formulation, which differ markedly between relugolix and depot agonists.
Option B: Option B is incorrect because relugolix binds reversibly, not irreversibly; recovery does not require regeneration of new receptors over many months — the existing receptors are freed as the drug clears.
Option C: Option C is incorrect because relugolix recovery is predictable and related to its short half-life; it does not cause years-long suppression, and permanent gonadotroph downregulation is not its mechanism.
Option D: Option D is incorrect because the faster recovery is driven by relugolix's short half-life and reversible binding, not merely by the oral route; a hypothetical long-half-life oral agent would not recover as quickly.
21. [CASE 6 — QUESTION 1]
A 69-year-old man with advanced prostate cancer and bulky nodal disease is started on degarelix because the team wishes to avoid a testosterone flare. A medical student asks how degarelix differs mechanistically from a GnRH agonist. Which of the following best describes the mechanism of degarelix?
A) Degarelix is a GnRH agonist that produces an initial receptor activation and testosterone surge before downregulating the receptor over 3 to 4 weeks
B) Degarelix blocks peripheral androgen receptors at the prostate, leaving serum testosterone elevated while preventing androgen-driven tumor growth
C) Degarelix inhibits 5-alpha-reductase, lowering dihydrotestosterone without changing serum testosterone or LH
D) Degarelix is a competitive, reversible GnRH receptor antagonist that blocks the receptor from the first dose without any initial activation, immediately suppressing LH and FSH and achieving castrate testosterone within about 3 days with no testosterone flare
E) Degarelix stimulates pituitary somatotrophs to increase growth hormone, indirectly lowering testosterone through a paracrine effect on the gonads
ANSWER: D
Rationale:
Degarelix is a competitive, reversible GnRH receptor antagonist. It blocks the GnRH receptor on pituitary gonadotrophs from the first dose, with no initial receptor activation, immediately suppressing LH and FSH and achieving castrate testosterone (below 50 ng/dL) within about 3 days — with no testosterone flare. This flare-free, rapid onset is exactly why it was chosen for this patient with bulky disease.
Option A: Option A is incorrect because degarelix is an antagonist, not an agonist; it produces no initial receptor activation or testosterone surge, and its onset (about 3 days) is far faster than the 3 to 4 weeks required by agonist depots.
Option B: Option B is incorrect because degarelix acts at the pituitary GnRH receptor to suppress gonadotropins and lower testosterone; it does not work by blocking peripheral androgen receptors while leaving testosterone elevated.
Option C: Option C is incorrect because degarelix does not inhibit 5-alpha-reductase; it suppresses LH and lowers serum testosterone, unlike 5-alpha-reductase inhibitors, which lower dihydrotestosterone without suppressing LH.
Option E: Option E is incorrect because degarelix does not stimulate growth hormone or act through a paracrine gonadal effect; it directly antagonizes the pituitary GnRH receptor.
22. [CASE 6 — QUESTION 2]
Continuing with the same patient. After several monthly degarelix injections, he reports pain, redness, and firm nodules at the injection sites that persist for 1 to 2 weeks after each dose. His testosterone is well suppressed at 14 ng/dL. Which of the following best characterizes this adverse effect and its mechanism?
A) Injection-site reactions including pain, erythema, and nodule formation occur in about 35 to 40% of patients on degarelix — substantially more often than with intramuscular leuprolide or goserelin — and result from the depot-gel mechanism in which the decapeptide self-aggregates into a hydrogel at the subcutaneous injection site, provoking local inflammation
B) These findings indicate a systemic IgE-mediated hypersensitivity reaction to degarelix; skin testing should be performed and the patient switched to a GnRH agonist
C) These reactions reflect complement-mediated anaphylaxis occurring in about 0.9% of patients, the mechanism that led to abarelix withdrawal, and degarelix should be discontinued immediately
D) These findings represent injection-site inflammation from testosterone flare and will resolve once medical castration is fully established after 2 to 3 injections
E) Injection-site nodules indicate that the drug is being delivered intramuscularly rather than subcutaneously, and switching to intramuscular injection will resolve the reactions
ANSWER: A
Rationale:
Injection-site reactions — pain, erythema, and palpable nodules — are the most clinically significant local adverse effect of degarelix, occurring in about 35 to 40% of patients, substantially more often than with intramuscular leuprolide or goserelin. The mechanism is specific to degarelix: it is a decapeptide that, when injected subcutaneously into the aqueous tissue environment, self-aggregates into a hydrogel depot at the site. This in-situ gel is both the sustained-release mechanism and the source of local inflammation. The reactions are generally self-limited and managed by rotating sites and supportive measures; the patient's testosterone of 14 ng/dL confirms effective suppression, so this is not a drug-failure issue.
Option B: Option B is incorrect because the reactions are local depot-related inflammation, not systemic IgE-mediated hypersensitivity; switching to an agonist for this reason is not indicated.
Option C: Option C is incorrect because complement-mediated anaphylaxis (about 0.9%) was the abarelix problem; degarelix was engineered to reduce that risk, and the 35 to 40% figure describes local injection-site reactions, not anaphylaxis.
Option D: Option D is incorrect because degarelix produces no testosterone flare, and these reactions recur with each injection rather than resolving after the initial period; they are not flare-related.
Option E: Option E is incorrect because degarelix is designed for subcutaneous administration, and the injection-site reactions arise from the subcutaneous hydrogel depot itself; switching to intramuscular injection would alter the controlled-release mechanism and is not the appropriate response.
23. [CASE 6 — QUESTION 3]
Continuing with the same patient. While reviewing the history of GnRH antagonists, the student asks why an earlier injectable antagonist, abarelix, was withdrawn from the US market, and how degarelix differs in that respect. Which of the following best explains the abarelix safety problem and the way degarelix was designed to address it?
A) Abarelix was withdrawn because it produced a more severe testosterone flare than agonists owing to partial agonist activity; degarelix avoids this by being a full antagonist
B) Abarelix was withdrawn because it caused permanent pituitary failure in a substantial fraction of patients; degarelix avoids this because its effect is reversible
C) Abarelix was withdrawn because it caused serious systemic allergic reactions, including anaphylaxis, in about 0.9% of patients, attributed to complement activation by the first-generation peptide backbone; degarelix was subsequently developed with a modified peptide structure that substantially reduces histamine-releasing and systemic allergic potential while retaining the GnRH antagonist mechanism
D) Abarelix was withdrawn because of excessive QT prolongation from a direct cardiac ion channel effect independent of testosterone; degarelix lacks any QT effect
E) Abarelix was withdrawn because it required daily oral dosing with poor adherence; degarelix improved adherence by being the first oral antagonist
ANSWER: C
Rationale:
Abarelix, the first injectable GnRH antagonist approved for prostate cancer in the US, was withdrawn because of serious systemic allergic reactions, including anaphylaxis, occurring in about 0.9% of patients. These reactions were attributed to complement activation and histamine release driven by structural features of the first-generation antagonist peptide backbone. This safety problem directly motivated the development of degarelix, which has a modified peptide structure engineered to substantially reduce histamine-releasing and systemic allergic potential while retaining the GnRH antagonist mechanism — which is why degarelix has a much lower rate of systemic allergic reactions (its main issue being local injection-site reactions instead).
Option A: Option A is incorrect because abarelix was a competitive antagonist, not a partial agonist; it did not produce a testosterone flare, so flare was not the reason for withdrawal.
Option B: Option B is incorrect because abarelix did not cause permanent pituitary failure; GnRH antagonist effects are reversible, and permanent pituitary failure is not an established abarelix toxicity.
Option D: Option D is incorrect because the abarelix withdrawal was driven by systemic allergic reactions/anaphylaxis, not by a direct cardiac ion channel QT effect; QT prolongation with GnRH analogs is mediated by testosterone suppression as a class effect.
Option E: Option E is incorrect because abarelix was an injectable agent, not an oral one, and its withdrawal was due to systemic allergic reactions, not oral adherence; degarelix is also injectable, not the first oral antagonist.
24. [CASE 6 — QUESTION 4]
Continuing with the same patient. He tolerates degarelix despite the injection-site reactions, and his disease is controlled. The student asks, more generally, in which clinical situations choosing a GnRH antagonist over a GnRH agonist depot actually changes outcomes. Which of the following best summarizes when the antagonist choice is most likely to matter?
A) The antagonist choice never changes outcomes; antagonists and agonists are interchangeable in all clinical situations, and selection is based solely on cost
B) The antagonist choice is most likely to matter when rapid testosterone suppression is needed or a flare is dangerous (for example, vertebral metastases with cord-compression risk or bulky symptomatic disease), when the patient has established cardiovascular disease (where relugolix showed a lower rate of major adverse cardiovascular events than leuprolide), and when non-castrate testosterone has occurred on agonist depot therapy
C) The antagonist choice matters only in patients with localized, low-risk disease who do not need rapid suppression, because antagonists are too slow for high-burden disease
D) The antagonist choice matters only because antagonists eliminate the need for any testosterone monitoring, simplifying long-term care regardless of disease features
E) The antagonist choice matters only in patients who cannot tolerate oral medications, since all antagonists are injectable and all agonists are oral
ANSWER: B
Rationale:
Choosing a GnRH antagonist over an agonist depot is most likely to change outcomes in specific situations: when rapid testosterone suppression is required or a testosterone flare is dangerous — such as vertebral metastases with cord-compression risk or bulky, symptomatic disease, where the antagonist's flare-free rapid onset is critical; when the patient has established cardiovascular disease, where the oral antagonist relugolix was associated with a lower rate of major adverse cardiovascular events than leuprolide in the HERO trial; and when non-castrate testosterone has occurred on agonist depot therapy, since antagonists maintain castrate levels more consistently in some comparisons.
Option A: Option A is incorrect because the antagonist choice does change outcomes in the situations above; antagonists and agonists are not interchangeable in all settings, and selection is not based solely on cost.
Option C: Option C is incorrect because antagonists are not too slow for high-burden disease — the opposite is true: their rapid, flare-free onset makes them especially valuable in high-burden symptomatic disease, not in low-risk disease that does not need rapid suppression.
Option D: Option D is incorrect because antagonists do not eliminate the need for testosterone monitoring; confirming castrate testosterone remains part of care regardless of agent.
Option E: Option E is incorrect because the antagonist advantage is not about oral intolerance, and the premise is wrong: degarelix is injectable while relugolix is oral, and agonists are injectable depots, so the oral-versus-injectable framing does not capture when the antagonist choice matters.
25. [CASE 7 — QUESTION 1]
A 66-year-old man has been on leuprolide depot for locally advanced prostate cancer for 12 months. He reports central weight gain, decreased muscle mass, and fatigue. His fasting glucose has risen from 92 to 120 mg/dL, his HDL (high-density lipoprotein) cholesterol has fallen from 48 to 33 mg/dL, and his triglycerides have risen from 130 to 240 mg/dL. Which of the following best explains the mechanism of this constellation?
A) These changes are a direct hepatotoxic effect of leuprolide on lipid and glucose metabolism; switching to degarelix will reverse them because degarelix is not hepatotoxic
B) These changes are caused by leuprolide-induced FSH suppression, which normally drives adipose lipolysis; an FSH-replacement supplement will resolve them within weeks
C) These changes reflect a drug-specific effect of the PLGA polymer carrier in the leuprolide depot; switching to goserelin, which uses a different matrix, will prevent further metabolic deterioration
D) These changes are due to estradiol elevation from peripheral aromatization during the initial testosterone flare and will resolve once castrate testosterone removes the aromatization substrate
E) These changes are consistent with the metabolic syndrome of sustained hypogonadism from androgen deprivation therapy — visceral adiposity, decreased lean muscle mass, insulin resistance, and dyslipidemia — a class effect of testosterone suppression that increases the risk of type 2 diabetes by about 40% and cardiovascular events by 10 to 20% over 1 to 5 years, managed with lifestyle intervention and metabolic and cardiovascular screening
ANSWER: E
Rationale:
This constellation — central weight gain, decreased muscle mass, rising fasting glucose, falling HDL, and rising triglycerides — is the classic metabolic syndrome of androgen deprivation therapy (ADT), a consequence of sustained hypogonadism. Testosterone is anabolic for skeletal muscle and anti-adipogenic; its suppression promotes visceral adiposity, loss of lean mass, insulin resistance, and dyslipidemia. This is a class effect of testosterone suppression, increasing the risk of type 2 diabetes by about 40% and major cardiovascular events by 10 to 20% over 1 to 5 years. Management includes lifestyle intervention (aerobic and resistance exercise, dietary modification) plus baseline and periodic metabolic and cardiovascular screening, with statin therapy and diabetes management as indicated.
Option A: Option A is incorrect because the metabolic syndrome is caused by testosterone suppression, not hepatotoxicity; switching to degarelix would not reverse it, since degarelix also suppresses testosterone.
Option B: Option B is incorrect because the changes result from testosterone suppression, not FSH suppression, and no FSH-replacement supplement exists or is indicated.
Option C: Option C is incorrect because the metabolic changes are a consequence of testosterone suppression and are unrelated to the polymer delivery system; switching polymer matrices does not alter the outcome.
Option D: Option D is incorrect because these changes are not caused by transient estradiol elevation during the flare; they develop progressively from sustained hypogonadism and persist throughout therapy rather than resolving once castrate levels are reached.
26. [CASE 7 — QUESTION 2]
Continuing with the same patient. Recognizing the metabolic changes, his oncologist establishes a structured monitoring program rather than tracking the cancer with PSA alone. Which of the following best describes an appropriate comprehensive monitoring program during ongoing androgen deprivation therapy?
A) PSA every 6 months only; testosterone, metabolic, and bone monitoring are unnecessary because PSA fully reflects all relevant effects of therapy
B) Weekly testosterone for the first 3 months and annual PSA, with no metabolic or bone monitoring unless the patient already has diabetes or osteoporosis
C) Annual PSA, annual testosterone, and a single DEXA at 5 years, because more frequent monitoring has not been shown to benefit men with suppressed PSA
D) PSA every 3 to 6 months; serum testosterone before each depot injection (or every 3 to 6 months for oral agents) to confirm castrate levels; a fasting metabolic panel (glucose, lipids, HbA1c) every 3 to 6 months; DEXA at baseline with periodic repeat (about every 12 months on continuous therapy); and assessment of mood and sexual dysfunction at visits
E) Monitoring identical to non-androgen-deprivation prostate cancer surveillance — PSA every 6 months and annual examination — with all metabolic and cardiac monitoring delegated entirely to primary care
ANSWER: D
Rationale:
Because ADT affects multiple organ systems through sustained testosterone deprivation, monitoring is multidimensional. An appropriate program includes PSA every 3 to 6 months to track disease; serum testosterone before each depot injection (or every 3 to 6 months for oral agents) to confirm castrate levels and detect non-castrate testosterone; a fasting metabolic panel (glucose, lipids, hemoglobin A1c [HbA1c]) every 3 to 6 months given the substantial risk of insulin resistance, diabetes, and dyslipidemia; DEXA at baseline with periodic repeat (about every 12 months on continuous therapy) for bone surveillance; and assessment of mood and sexual dysfunction, which are common and underreported.
Option A: Option A is incorrect because PSA alone does not capture the metabolic, bone, testosterone, and neuropsychiatric effects of ADT; testosterone and metabolic and bone monitoring are essential.
Option B: Option B is incorrect because weekly testosterone is not standard (testosterone is checked at injection visits or every 3 to 6 months), and metabolic and bone monitoring are recommended for all ADT patients, not only those with preexisting conditions.
Option C: Option C is incorrect because annual PSA and a single 5-year DEXA are inadequate; PSA and testosterone should be checked every 3 to 6 months, and DEXA repeated about annually on continuous therapy.
Option E: Option E is incorrect because metabolic and bone monitoring are integral to oncologic care during ADT and should be managed by the prescribing team in collaboration with other providers, not delegated entirely to primary care.
27. [CASE 7 — QUESTION 3]
Continuing with the same patient. He reports frequent, disruptive hot flashes that interfere with sleep and quality of life. His cancer remains well controlled. He asks for help managing the hot flashes. Which of the following is the most appropriate pharmacologic option?
A) A nonhormonal agent such as venlafaxine or gabapentin (medroxyprogesterone acetate is another option) effectively reduces androgen-deprivation hot flashes, while estrogen-based therapy is contraindicated in prostate cancer
B) Transdermal estradiol, because estrogen replacement is the most effective hot flash treatment and carries no oncologic risk in men with prostate cancer
C) A short course of high-dose testosterone to counteract the hypogonadal symptom, while maintaining cancer control
D) Discontinuation of leuprolide, because hot flashes indicate that androgen deprivation therapy is no longer tolerable and must be stopped
E) Finasteride, because 5-alpha-reductase inhibition relieves hot flashes by restoring dihydrotestosterone signaling in thermoregulatory centers
ANSWER: A
Rationale:
Hot flashes are the most common symptomatic adverse effect of GnRH-mediated hypogonadism, occurring in 50 to 80% of men on androgen deprivation therapy (ADT). Appropriate options are nonhormonal agents — venlafaxine, gabapentin, or medroxyprogesterone acetate — which reduce hot flash frequency and severity without stimulating the cancer. Importantly, estrogen-based hot flash therapy is contraindicated in prostate cancer.
Option B: Option B is incorrect because estrogen-based therapy is contraindicated in prostate cancer; the claim that it carries no oncologic risk in these men is wrong, which is precisely why nonhormonal agents are preferred.
Option C: Option C is incorrect because high-dose testosterone would stimulate prostate cancer growth and undermine the goal of ADT; it cannot be used to treat hot flashes in this setting.
Option D: Option D is incorrect because hot flashes are a manageable adverse effect and do not mandate discontinuing effective cancer therapy; symptomatic treatment with nonhormonal agents allows ADT to continue.
Option E: Option E is incorrect because finasteride does not treat ADT-related hot flashes; 5-alpha-reductase inhibition does not relieve vasomotor symptoms in this context, and the premise about restoring dihydrotestosterone signaling is incorrect, since the patient is already profoundly androgen-deprived by design.
28. [CASE 7 — QUESTION 4]
Continuing with the same patient. His clinical situation evolves: he completed local therapy, and his current disease state is a biochemical (PSA-only) recurrence with no radiographic evidence of metastases. He has achieved an undetectable PSA nadir on androgen deprivation therapy and is troubled by fatigue, hot flashes, and loss of libido. He asks whether he can take breaks from therapy. Which of the following best describes his candidacy for intermittent androgen deprivation therapy?
A) He is not a candidate, because intermittent androgen deprivation therapy is contraindicated in any patient with a prior rising PSA, as treatment holidays accelerate castration-resistant disease and worsen survival
B) He is an appropriate candidate: in men with biochemically recurrent, non-metastatic prostate cancer who achieve a good PSA nadir, intermittent androgen deprivation therapy provides overall survival comparable to continuous therapy while allowing partial testosterone recovery during off-cycles that can mitigate fatigue, hot flashes, and other long-term effects of sustained hypogonadism
C) He is a candidate only after he develops radiographic metastases, because intermittent therapy has proven survival benefit exclusively in metastatic disease
D) He is not a candidate because intermittent therapy requires an oral GnRH antagonist; depot agonists cannot be used because testosterone recovery after a depot is too slow to allow any off-cycle
E) He is a candidate, but treatment holidays should begin immediately from the start of therapy rather than after a PSA nadir, because starting holidays before full suppression preserves testicular function
ANSWER: B
Rationale:
The strongest evidence for intermittent androgen deprivation therapy (ADT) — comparable overall survival to continuous ADT — applies to men with biochemically recurrent, non-metastatic prostate cancer who achieve a good PSA nadir. This patient fits: PSA-only recurrence, no radiographic metastases, and an undetectable PSA nadir on ADT. Intermittent therapy allows partial testosterone recovery during off-cycles, which can mitigate the long-term consequences of sustained hypogonadism troubling him — fatigue, hot flashes, sexual dysfunction, and also metabolic and bone effects — without compromising survival. He is therefore an appropriate candidate.
Option A: Option A is incorrect because intermittent ADT does not significantly worsen survival in biochemically recurrent non-metastatic disease; randomized data show comparable overall survival, and it is a supported option in this setting.
Option C: Option C is incorrect because the comparable-survival evidence applies specifically to biochemically recurrent non-metastatic disease, not metastatic disease where continuous ADT is standard; he need not develop metastases to qualify.
Option D: Option D is incorrect because intermittent ADT can be delivered with depot agonists, which were used in most intermittent-therapy trials; although recovery after a depot is slower, off-cycle intervals are still feasible and beneficial.
Option E: Option E is incorrect because intermittent ADT protocols begin treatment holidays only after a confirmed PSA nadir and sustained suppression; starting holidays before adequate suppression would provide neither the oncologic benefit of ADT nor meaningful off-cycle recovery.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.